C4 Therapeutics Inc
NASDAQ:CCCC
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.18
11
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
C4 Therapeutics Inc
EV/FCFF
Enterprise Value to FCFF
Enterprise Value to Free Cash Flow To Firm (EV/FCFF) ratio is a valuation multiple that compares the value of a company, debt included, to the amount of free cash flow available for all stakeholders. This metric is very similar to the EV/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.
| Market Cap | EV/FCFF | ||||
|---|---|---|---|---|---|
| US |
|
C4 Therapeutics Inc
NASDAQ:CCCC
|
302m USD | -0.6 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -238 095.9 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
320.1B USD | 23.8 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
147.4B USD | 31.1 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
119.4B USD | -82.6 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
113.8B USD | 10.9 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -471.1 | |
| AU |
|
CSL Ltd
ASX:CSL
|
135.4B AUD | 64.9 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82.6B USD | 22.8 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -56.8 | |
| NL |
|
argenx SE
XBRU:ARGX
|
34.3B EUR | -100.8 |
EV/FCFF Forward Multiples
Forward EV/FCFF multiple is a version of the EV/FCFF ratio that uses forecasted free cash flow to firm for the EV/FCFF calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to firm forecasts for 1, 2, and 3 years ahead, respectively.
You don't have any saved screeners yet
